Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
1993-01-31
1998-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurobiology of Opioid Dependence: 3 - 3
NCT00000194
Influence of Medication on Functional Connectivity
NCT03612713
Mapping Ibogaine Neural Dynamics in Opioid Use Disorder
NCT07226570
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
NCT06160284
The Effects of ∆-9-THC and Naloxone in Humans
NCT01591629
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lamotrigine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marc I Rosen, M.D.
Role: PRINCIPAL_INVESTIGATOR
VA Connecticut Healthcare System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Connecticut Healthcare System
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rosen MI, Pearsall HR, Kosten TR. The effect of lamotrigine on naloxone-precipitated opiate withdrawal. Drug Alcohol Depend. 1998 Oct 1;52(2):173-6. doi: 10.1016/s0376-8716(98)00057-x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
K20-00191-1
Identifier Type: -
Identifier Source: secondary_id
NIDA-00191-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.